Kindred Biosciences, Inc. Press releases
Feb 06, 2014
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that members of its senior management team will participate in a fireside chat presentation at the 2014 Leerink Global.
Aug 22, 2013
Kindred Bio Appoints Dr. Stephen Sundlof, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as Senior Vice President of Regulatory Affairs
Aug 06, 2013
CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.
Jul 02, 2013
Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the Kindred Bio team
Jul 02, 2013
FDA issues the equivalent of a Special Protocol Assessment on the design of KIND-001 and KIND-002 Pivotal Studies
Mar 26, 2013
KIND-005 is expected to be a major new therapy for the treatment of laminitis in...
Feb 01, 2013
KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs.
Jan 22, 2013
Highly Regarded Veterinary Marketing Executive to Join Kindred Bio’s Board
Dec 31, 2012
KIND-001, a potent and specific inhibitor of inflammatory cytokines, is expected to be a major new therapy for diseases in dogs.
Nov 05, 2012
Distinguished Pharmaceutical Executive to Join Kindred Bio’s Board